Related Experiment Video
Updated: Aug 23, 2025
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
Published on: September 8, 2023
Biomarker-Targeted Therapies in Non-Small Cell Lung Cancer: Current Status and Perspectives
Haiyang Guo1,2, Jun Zhang1,3, Chao Qin1,3
1Department of Thoracic Surgery, Suining Central Hospital, Suining 629099, China.
Abstract:
Non-small-cell lung cancer (NSCLC) is one of the most common malignancies and the leading causes of cancer-related death worldwide. Despite many therapeutic advances in the past decade, NSCLC remains an incurable disease for the majority of patients. Molecular targeted therapies and immunotherapies have significantly improved the prognosis of NSCLC. However, the vast majority of advanced NSCLC develop resistance to current therapies and eventually progress. In this review, we discuss current and potential therapies for NSCLC, focusing on targeted therapies and immunotherapies. We highlight the future role of metabolic therapies and combination therapies in NSCLC.
Insights
Non-small-cell lung cancer (NSCLC) treatments are advancing, but resistance remains a challenge. This review explores targeted, immune, metabolic, and combination therapies for better NSCLC outcomes.
Area of Science:
- Oncology
- Cancer Research
- Pulmonology
Background:
- Non-small-cell lung cancer (NSCLC) is a leading cause of cancer death globally.
- Despite advances, NSCLC remains largely incurable, with frequent therapeutic resistance.
- Current treatments include targeted therapies and immunotherapies, offering improved but not definitive outcomes.
Purpose of the Study:
- To review current and emerging therapies for non-small-cell lung cancer.
- To focus on targeted therapies and immunotherapies in NSCLC treatment.
- To highlight the potential of metabolic and combination therapies for advanced NSCLC.
Main Methods:
- Literature review of recent advancements in NSCLC therapy.
- Analysis of targeted therapy and immunotherapy efficacy and resistance mechanisms.
- Exploration of novel therapeutic strategies, including metabolic and combination approaches.
Main Results:
- Targeted therapies and immunotherapies have improved NSCLC prognosis.
- Therapeutic resistance is a significant obstacle in advanced NSCLC.
- Metabolic and combination therapies show promise for overcoming resistance.
Conclusions:
- Continued research into NSCLC therapies is crucial.
- Targeted, immune, metabolic, and combination strategies are key to improving patient outcomes.
- Addressing therapeutic resistance is paramount for advancing NSCLC treatment.
More Related Videos
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...